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and immune defenses contained in the tumor microenvironment. 
We believe that in the near future, breast cancer treatment will be 
more tailored to both the individual and the tumor. There will be 
more investment in trials in the neoadjuvant setting in order to 
identify active drugs for further clinical development and to find 
biomarkers of response. Another potential approach for the future 
will be the use of gene expression arrays. Specific gene expression 
signatures have been proposed to predict potential benefit form 
chemotherapy of extended endocrine therapy [1–9]. 
The ‘holy grail’ of personalized cancer care, the major ambition 
of current translational research, will remain elusive unless we can 
find ways to identify specifically those individual patients who ben-
efit from a given systemic therapy, avoiding the risk of overtreat-
ment. To accomplish this we require a change in the way trials are 
designed to investigate a new therapy or a new therapeutic ap-
proach, but we also need to confirm that the de-escalation of inter-
ventions previously regarded as standard of care in some groups of 
patients can be achieved without harm. What is the level of abso-
lute benefit that is required before accepting a new therapeutic 
 approach as a standard of care? Escalation trials are more success-
ful than de-escalation trials. Estimating the magnitude of clinical 
benefit and the perceptions of appropriate efficacy-toxicity rela-
tionships to design trials will yield more relevant results in the 
 future treatment of early breast cancer.
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The aim of this special issue of Breast Care is to focus on 
areas of ‘escalation’ or ‘de-escalation’ in the adjuvant treatment of 
early breast cancer. That is, to identify areas where optimal care 
may be achieved with ‘less’ or ‘more’ treatment. 
Avoidance of unnecessary or ineffective treatment should be one 
of the main goals in adjuvant breast oncology today. ‘Do not harm’ 
remains the main principle in medicine. To be able to follow this 
rule, we need to better understand the biology of breast cancer. The 
risk of overtreatment is real and the selection of precisely defined 
cohorts for clinical trials is necessary, despite the pressure of scien-
tific ambition, pragmatism, and demands of industry. The ‘add on’ 
clinical trial design model accepts the inability to confirm that 
standard therapy is still necessary if a positive result from the addi-
tion of the new therapy is obtained. The same model can be applied 
to ‘extended’ adjuvant treatments in breast cancer subtypes. It is 
 essential to escalate treatment when necessary and to de-escalate 
when unnecessary. Precise tools to optimally select  patients and 
regimens for adjuvant chemotherapy in early breast cancer are 
missing. We need to discover biomarkers that could help identify-
ing patients who are more likely to benefit from  chemotherapy. 
Research that aims at understanding the complexity of resist-
ance to a given chemotherapy agent and the way in which resist-
ance can be overcome is essential. Appreciation of additional di-
versity in biology and treatment sensitivity within the intrinsic 
breast cancer subtypes requires new approaches to personalize 
treatment as much as possible and to maximize efficacy. To achieve 
this goal it is fundamental to identify the functional biological tar-
gets, the cell pathway functions, the intra-tumoral biological het-
erogeneity, and influential host features, mostly the host stroma 
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